Texas Permanent School Fund Ironwood Pharmaceuticals Inc Transaction History

Texas Permanent School Fund

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 07, 2024	SELL	$5.58 - $8.61 $97,147 - $149,900	-17,410 Reduced 14.48%	102,835 $670,000
Q1 2024 May 03, 2024	BUY	$8.32 - $15.45 $12,954 - $24,055	1,557 Added 1.31%	120,245 $1.05 Million
Q4 2023 Feb 08, 2024	BUY	$8.79 - $11.51 $18,248 - $23,894	2,076 Added 1.78%	118,688 $1.36 Million
Q3 2023 Nov 09, 2023	SELL	$8.25 - $11.35 $19,684 - $27,081	-2,386 Reduced 2.01%	116,612 $1.12 Million
Q2 2023 Aug 07, 2023	SELL	$10.1 - $11.6 $6,898 - $7,922	-683 Reduced 0.57%	118,998 $1.27 Million
Q1 2023 May 01, 2023	BUY	$10.37 - $12.56 $310,705 - $376,322	29,962 Added 33.4%	119,681 $1.26 Million
Q4 2022 Feb 07, 2023	SELL	$9.9 - $12.43 $60,954 - $76,531	-6,157 Reduced 6.42%	89,719 $1.11 Million
Q3 2022 Oct 25, 2022	BUY	$10.14 - $12.38 $216,783 - $264,672	21,379 Added 28.7%	95,876 $993,000
Q2 2022 Aug 08, 2022	BUY	$11.05 - $12.72 $823,191 - $947,601	74,497 New	74,497 $859,000

238

162M

11.2M

9.1K

Ticker IRWD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 153,231,008
Market Cap $541M
Description
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZE...

Get notified when there are updates to the investment portfolio of Texas Permanent School Fund, based on Form 13F filings with the SEC.

Stay updated on Texas Permanent School Fund with notifications on news.